For example, blockade of both the classical and trans-signaling IL-6 pathways using the animal-equivalent (MR16-1) of tocilizumab had no effect on AAA rupture in the Ang II + anti-TGF-β model, but it was associated with decreased survival in the elastase + anti-TGF-β model. This evidence concerns the gene TGFB1 and triple-A syndrome.